HIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts

Lenacapavir, an injectable HIV prevention drug requiring only two annual injections, offers significant promise for reducing HIV cases globally with 99% effectiveness. However, experts warn that cuts to US foreign aid will prevent widespread access to this innovation in the regions that need it most, undermining its potential public health impact.